SCHEMBL2848543

SCHEMBL2848543

CN(CCc1ccccn1)S(=O)(=O)c1cccc(N)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.64
SMN1; SMN2 Q16637 3/20 0.64
MAPT P10636 1/20 0.64
HSD17B10 Q99714 2/20 0.56
ALDH1A1 P00352 4/20 0.47
HPGD P15428 1/20 0.47
CASP1 P29466 1/20 0.47
CASP7 P55210 1/20 0.47
GAA P10253 2/20 0.46
KMT2A Q03164 2/20 0.44
CYP2D6 P10635 2/20 0.44
CYP2C9 P11712 2/20 0.44
CYP2C19 P33261 2/20 0.44
TSHR P16473 2/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
RECQL P46063 1/20 0.43
LMNA P02545 1/20 0.42
PKM P14618 1/20 0.42
SLC12A2 P55011 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3300509 0.86 KDM4E (0.76) KDM4ESMN1; SMN2MAPTHSD17B10ALDH1A1
SCHEMBL2848539 0.83 KDM4E (0.59) KDM4ESMN1; SMN2MAPTHSD17B10ALDH1A1
SCHEMBL14419624 0.83 KDM4E (0.65) KDM4ESMN1; SMN2MAPTHSD17B10ALDH1A1
SCHEMBL10860489 0.81 LMNA (0.55) SMN1; SMN2HSD17B10ALDH1A1KMT2ATSHR
SCHEMBL14574205 0.77 LMNA (0.50) SMN1; SMN2HSD17B10ALDH1A1KMT2ATSHR
SCHEMBL2852904 0.76 KMT2A (0.56) KDM4EMAPTHSD17B10ALDH1A1GAA
SCHEMBL8251507 0.73 LMNA (0.53) SMN1; SMN2HSD17B10ALDH1A1TSHRLMNA
SCHEMBL6749782 0.73 KDM4E (0.61) KDM4ESMN1; SMN2MAPTHSD17B10ALDH1A1
SCHEMBL9447106 0.73 CYP2D6 (0.74) KDM4EALDH1A1CYP2D6CYP2C9CYP2C19
Hydrochloric Acid SCHEMBL7542981 0.73 HSD17B10 (0.63) KDM4ESMN1; SMN2MAPTHSD17B10ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1451160-B1 PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN ICAGEN INC (US) 2010-01-13 EP claimed
EP-1451160-B1 PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN ICAGEN INC (US) 2010-01-13 EP disclosed
US-7223782-B2 Pyrazole-amides and -sulfonamides ICAGEN, INC. (US) 2007-05-29 US disclosed
US-20050049237-A1 Pyrazole-amides and -sulfonamides ICAGEN, INC. (US) 2005-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050049237-A1 Pyrazole-amides and -sulfonamides SCN3A, TRPV3, HCN3 KDM4E 2869/4885SMN1; SMN2 599/4885MAPT 3590/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.